Loading stock data…
Monte Rosa Therapeutics, Inc. (GLUE)
$23.90+1.61 (+7.22%)
After Hours$23.97+0.07 (+0.29%)· Last close Jun 29
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Monte Rosa Therapeutics, Inc. in the Healthcare sector is trading at $23.90 with a market capitalization of $1.5B. Wall Street consensus targets $32.33 (6 analysts), implying a +35.3% move over the next 12 months. The stock is currently near its 52-week high of $25.77, remaining 46.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.21M↑ | $2.78M↓ | $12.77M↓ | $23.19M↓ | $84.93M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.03M↓ | -$49.72M↓ | -$32.98M↓ | -$15.55M↓ | $44.04M |
| Net Income | -$44.50M↑ | -$46.13M↓ | -$27.08M↓ | -$12.29M↓ | $46.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.91%
Volume
Today's trading volume
1.84M
Recent News
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) is one of the best growth stocks under $20 to buy. On May 7, Monte Rosa reported progress across its clinical-stage pipeline, with three programs advancing toward Phase 2 studies. MRT-8102, an NEK7-directed molecular glue degrader/MGD for inflammatory diseases, showed significant CRP reductions in early trials. The company plans to […]
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
Monte Rosa Therapeutics, NasdaqGS: GLUE, reported positive interim clinical results for several molecular glue degrader programs. The company plans to start multiple Phase 2 studies for MRT-8102 in cardiovascular risk patients and MRT-2359 in metastatic prostate cancer in the upcoming year. The updates come as the stock trades at $19.81, with strong recent share price performance. For investors watching Monte Rosa Therapeutics, NasdaqGS: GLUE, the new data arrives after a strong run in the...
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?